173191-89-4

Upstream product

• 103789-66-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)-benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 103788-61-0 (5-methyl-2-phenyl-4-oxazolyl)methyl chloride 

Downstream Products

• 173191-90-7 N-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)benzyl]-hydroxylamine 

Relevant academic research and scientific papers

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

N-HYDROXYUREAS AS 5-LIPOXYGENASE INHIBITORS AND INHIBITORS OF OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN

This invention relates to compounds having 5-lipoxygenase inhibiting properties and inhibition of oxidative modification of low density lipoprotein which have the formula: wherein: R1 and R3 are independently hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy,